3Vote!
SchaeffersResearch.com Trading Floor Blog (Free subscription) | yesterday
Here are the stocks that saw a bias toward put activity in the previous session.This filtered scan is based on the International Securities Exchange (ISE) buy-to-open data...( Read More )
3Vote!
Radon Mitigation Pittsburgh (Free subscription) | 12 hours ago
... plunged 16.07% to $0.940 on 1.09 million shares after the company announced that its partner Keryx Biopharmaceuticals reported updated efficacy and safety data as well as new survival data on the clinical activity of perifosine (KRX-0401) in combination with bortezomib (Velcade) (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma. KongZhong Corporation (ADR) (NASDAQ:KONG)...
5Vote!
Stock Market Analysis (Free subscription) | yesterday
... Morgans Hotel Group Co. (MHGC) Advanced Micro Devices Inc. (AMD) SunPower Corporation (SPWRA) Keryx Biopharmaceuticals Inc. (KERX) China Agritech Inc. (CAGC) SmartHeat Inc. (HEAT) Suntech Power Holdings Co. Ltd. (STP) More............ Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/...
Explore : AMD,
Business,
Components,
Computer industry,
Electronics,
Graphic Cards,
Hardware,
McDermott International,
NVIDIA Corporation,
Semi Conductors,
SunPower Corporation,
Suntech Power Holdings
4Vote!
Miami Herald (Free subscription) | 12/02/2009
Keryx Biopharmaceuticals Inc. and AEterna Zentaris Inc. said Wednesday the Food and Drug Administration granted the potential cancer treatment Perifosine a fast-track review process.
7Vote!
Seattle Times (Free subscription) | 12/02/2009
Keryx Biopharmaceuticals Inc. and AEterna Zentaris Inc. said Wednesday the Food and Drug Administration granted the potential cancer treatment Perifosine a fast-track review process.
7Vote!
Seattle Post-Intelligencer (Free subscription) | 12/02/2009
NEW YORK -- Keryx Biopharmaceuticals Inc. and AEterna Zentaris Inc. said Wednesday the Food and Drug Administration granted the potential cancer treatment Perifosine a fast-track review process.
7Vote!
Seattle Post-Intelligencer (Free subscription) | 12/02/2009
NEW YORK -- Keryx Biopharmaceuticals Inc. and AEterna Zentaris Inc. said Wednesday the Food and Drug Administration granted the potential cancer treatment Perifosine a fast-track review process.
5Vote!
Red Orbit (Free subscription) | 12/02/2009
NEW YORK, Dec. 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the U.S.
5Vote!
PR News Wire (Free subscription) | 12/02/2009
... compound, perifosine (KRX-0401), for the treatment of relapsed/refractory multiple myeloma. Keryx Biopharmaceuticals, Inc. ("Keryx") (Nasdaq: KERX), is AEterna Zentaris' partner and licensee for perifosine in the United States, Canada and Mexico. Perifosine is also out-licensed to Handok in South Korea while AEterna Zentaris retains rights for the rest of the world.
5Vote!
PR News Wire (Free subscription) | 12/02/2009
NEW YORK, Dec. 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple...
